Items Tagged ‘pembrolizumab’

October 27th, 2016

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing

By

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with advanced stage lung cancer still die from their disease. Precision medicine continues to impact the lives […]

View full entry

Tags: General Lung Cancer, immune response, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, nsclc, opdivo, PD-1 inhibitors, pembrolizumab, precision medicine


October 19th, 2016

Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer

By

Researchers presented full results of Keytruda® (pembrolizumab) and Opdivo® (nivolumab) in previously untreated advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology annual meeting in Copenhagen. An additional study was also recently published in the New England Journal of Medicine evaluating Keytruda in previously treated patients with advanced NSCLC . Results of […]

View full entry

Tags: 2016, advanced, ESMO, General Lung Cancer, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, opdivo, PD-1, pembrolizumab


September 14th, 2016

FDA Grants Breakthrough Therapy Designation to Keytruda® for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Keytruda® (pembrolizumab) for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The FDA’s Breakthrough Therapy Designation is intended to expedite the development and review of a drug that is planned for use to treat a serious or life-threatening disease […]

View full entry

Tags: advanced, General Lung Cancer, KEYNOTE-024, Lung Cancer, Lung Cancer - Non-Small Cell, Merck, News, nsclc, pembrolizumab, Stages IIIB-IV Lung Cancer - Non-Small Cell


September 7th, 2016

Keytruda® Approved for Advanced Head and Neck Cancer

By

The United States Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) for the treatment of advanced head and neck cancer that has stopped responding to platinum-based chemotherapy agents.1 Globally, head and neck cancer comprises the seventh most common type of cancer with an estimated 400,000-600,000 diagnoses every year. Head and neck squamous cell cancer […]

View full entry

Tags: advanced, fda, General Head and Neck Cancer, Head and Neck Cancer, keytruda, metastatic, News, pembrolizumab


June 14th, 2016

Promising Activity of Pembrolizumab in Merkel Cell Carcinoma

By

Treatment of 26 patients with advanced previously untreated Merkel cell carcinoma with Keytruda® (pembrolizumab) every three weeks resulted in an overall response rate of 56% suggesting this novel therapy could represent a new treatment option for these hard to treat cancers. Merkel cell carcinoma is a rare aggressive skin cancer with limited treatment options for […]

View full entry

Tags: General Skin Cancer, keytruda, Merkel cell carcinoma, News, pembrolizumab, Skin Cancer


June 6th, 2016

PD-1 Inhibitor Keytruda® Combined with Chemotherapy Promising in Lung Cancer Will be Evaluated in Larger Clinical Trials

By

According to experts at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, new data evaluating Keytruda® (pembrolizumab) in combination with chemotherapy appears promising for the treatment of non-small cell lung cancer (NSCLC). Based on these initial results, two comparative clinical trials have been initiated. The programmed death (PD-1) inhibitor Keytruda (pembrolizumab) […]

View full entry

Tags: fda, immunotherapy, KEYNOTE-189, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, PD-1 inhibitor, pembrolizumab


October 13th, 2015

FDA Approves Keytruda® for Lung Cancer

By

The programmed death (PD-1) inhibitor Keytruda® (pembrolizumab) has been granted approval by the US Food and Drug Administration (FDA) for use in lung cancer, becoming the first PD-1 inhibitor and the second immunotherapy available for treatment of this disease. PD-1 is a protein that inhibits certain types of immune responses. Drugs that block PD-1, such […]

View full entry

Tags: General Lung Cancer, KEYNOTE-001 trial, keytruda, Lung Cancer, News, PD-1 inhibitor, PD-L1, pembrolizumab


June 8th, 2015

Keytruda® Promising in Advanced Head and Neck Cancer

By

The immunotherapy Keytruda® (pembrolizumab) appears active in the treatment of advanced squamous cell head and neck cancer. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the Journal of Clinical Oncology.[i] Head and neck cancers originate in the tissues in or […]

View full entry

Tags: Head and Neck Cancer, keytruda, News, pembrolizumab


April 20th, 2015

Keytruda® May Be More Effective than Yervoy® in Advanced Melanoma

By

Keytruda® (pembrolizumab) appears to outperform Yervoy® (ipilimumab) at initial treatment of patients with advanced melanoma. Pharmaceutical company Merck announced these Phase III clinical trial findings in a press release in March 2015. Melanoma is less common than non-melanoma skin cancer, but tends to be much more aggressive. What makes melanoma so dangerous is that it […]

View full entry

Tags: advanced melanoma, ipilimumab, KEYNOTE-006, keytruda, Melanoma, News, pembrolizumab, Stage III Melanoma, Stage IV Melanoma, Yervoy


December 23rd, 2014

Keytruda PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma

By

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researchers at the American Society of Hematology (ASH) 56th Annual Meeting, PD-1 blockade has demonstrated efficacy in patients with Hodgkin lymphoma (HL). Hodgkin’s lymphoma is […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, HD, hodgkin's disease, Hodgkin's Lymphoma, keytruda, Lymphoma, News, pembrolizumab, Progressive Relapsed Hodgkin's Lymphoma


November 14th, 2014

Progress in the Treatment of Advanced Melanoma and Other Skin Cancers

By

By one estimate, over the past three decades more people in the United States have had skin cancer than all other cancers combined.1 According to the American Cancer Society, 3.5 million cases of basal and squamous cell skin cancer are diagnosed each year.2 Rates of melanoma—the deadliest form of skin cancer—are on the rise,2 particularly […]

View full entry

Tags: anti-PD-1, basal cell, General Skin Cancer, keytruda, Melanoma, News, pembrolizumab, Recurrent Melanoma, Skin Cancer, Skin Cancer Overview, Stage III Melanoma, Stage IV Melanoma


September 5th, 2014

Pembrolizumab Gets FDA Approval in Advanced Melanoma

By

The U.S. Food & Drug Administration (FDA) has granted approval to Merck’s new immunotherapy drug, Keytruda (pembrolizumab), for treating metastatic melanoma.   It is the first anti-PD-1 drug, aimed at re-energizing a patient’s protective immune response to cancer to have received FDA approval in the U.S. Of the more than one million new diagnoses of skin […]

View full entry

Tags: anti-PD-1, Melanoma, News, pembrolizumab, Recurrent Melanoma, Stage IV Melanoma


August 27th, 2014

Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer

By

Advaxis, Inc.a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck to evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer. Both ADXS-PSA and pembrolizumab are investigational members of […]

View full entry

Tags: ADXS-PSA, Metastatic Stage IV (D) Prostate Cancer, News, pembrolizumab, Prostate Cancer, Refactory/Recurrent Prostate Cancer


August 4th, 2014

Pembrolizumab Appears Promising in Treatment of Non-Small Cell Lung Cancer

By

Results from an ongoing Phase Ib study indicate that treatment with the experimental anti-PD-1 antibody pembrolizumab resulted in high response rates and slowed cancer progression in previously untreated stage IV non–small cell lung cancer (NSCLC). These results were recently presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO 2014) in […]

View full entry

Tags: Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, PD-1, pembrolizumab, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell


July 31st, 2014

Largest Study to Date of Pembrolizumab in Advanced Melanoma Shows Promising Activity

By

The investigational anti-PD-1 antibody pembrolizumab is demonstrating promising survival rates among patients with advanced melanoma. Data from an ongoing Phase 1 trial of the drug were presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO 2014) in Chicago in June. Of the more than one million new diagnoses of skin cancer […]

View full entry

Tags: Melanoma, News, PD-1, pembrolizumab, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma